Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR0302 in Active Non-Radiographic Axial Spondyloarthritis
NCT05324631Phase 3Unknown
- Sponsor
- Hengrui
- Start
- Aug 2022
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ivarmacitinib in non-radiographic axial spondyloarthritis (nr-axSpA), sponsored by Hengrui. Primary endpoint: Assessment of SpondyloArthritis International Society 40 Response at Week 12. Status: unknown.
02
Drugs
ivarmacitinib
03
Conditions
non-radiographic axial spondyloarthritis (nr-axSpA)
Beyond the preview
Go deeper on NCT05324631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05324631.